CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Ocoxin-Viusiddietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03562897
NCT03562897Phase 2Completed
CompareCT.gov

Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.

Catalysis SL·interventional·Posted Jun 20, 2018·Updated Jul 6, 2022

In Brief

A Phase 2 clinical trial evaluating Ocoxin-Viusid for Carcinoma and 12 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Ovarian Neoplasm, Endocrine Gland Neoplasm, Urogenital Neoplasms, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Endocrine System Diseases, Gonadal Disorders, Genital Neoplasm, Female, Neoplasms, Glandular and Epithelial
CountriesCuba
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 20, 2018
Enrollment StartOct 25, 2018
Primary CompletionFeb 15, 2022
Study CompletionJun 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.0 years ago

Interventions

Ocoxin-Viusiddietary

Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).